Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | completed | Phase 2 | 25 | Joseph TuscanoOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01025778 | Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | completed | Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01912274 |
| Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| completed |
| Phase 2 |
| 50 |
| Helsinn Healthcare SAINDUSTRY |
| 1 |
| Feb 9, 2021 |
| clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT00469014 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01180322 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine(azacitidine) | completed | Phase 2 | 277 | University of UlmOTHER | 2 | Dec 31, 2020 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00831766 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00005797 | Bone Marrow Transplant in Treating Patients With Hematologic Cancers | completed | Phase 2 | 125 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT00067028 | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | completed | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01279473 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02046122 | Adoptive Transfer of Haplo-identical DLI for AML and MDS | completed | Phase 1 / Phase 2 | 19 | Duke UniversityOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02799147 | GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia | completed | Phase 1 / Phase 2 | 27 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT00305682 | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | completed | Phase 2 | 295 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT02092324 | Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia | completed | Phase 2 | 51 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT01914484 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | completed | Phase 1 / Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03338348 | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | completed | Phase 2 | 9 | University of UlmOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT02458235 | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | completed | Phase 2 | 17 | University of California, San FranciscoOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02763475 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | completed | Phase 2 | 7 | Instituto de Investigación Hospital Universitario La PazOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01910012 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia | completed | Phase 2 | 43 | Polaris GroupINDUSTRY | 2 | Oct 1, 2020 | clinicaltrials |
| NCT00309842 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | completed | Phase 2 | 213 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01274351 | Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | completed | Phase 2 | 112 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 1, 2020 | clinicaltrials |
| NCT01885897 | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | completed | Phase 1 / Phase 2 | 33 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03820908 | Bisantrene for Relapsed /Refractory AML | completed | Phase 2 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT01830361 | Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML(MIDOKIT) | completed | Phase 2 | 18 | Technische Universität DresdenOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT01235572 | Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy | completed | Phase 2 | 200 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00274820 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder | completed | Phase 2 | 15 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01866839 | Preventing Stem Cell Transplant Complications With a Blood Separator Machine | completed | Phase 1 / Phase 2 | 41 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02405338 | DC Vaccination for Post-remission Therapy in AML | completed | Phase 1 / Phase 2 | 20 | Medigene AGINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT01369498 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | completed | Phase 2 | 54 | Gilead SciencesINDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01477606 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | completed | Phase 2 | 451 | University of UlmOTHER | 2 | Jun 4, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT01370213 | NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases | completed | Phase 2 | 25 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 13, 2020 | clinicaltrials |
| NCT02560025 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | completed | Phase 2 | 70 | medac GmbHINDUSTRY | 6 | May 4, 2020 | clinicaltrials |
| NCT01252667 | Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 44 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT01787552 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | completed | Phase 1 / Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 15, 2020 | clinicaltrials |
| NCT02530476 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT03170895 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | completed | Phase 2 | 5 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT03622541 | Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT02252107 | 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1 | completed | Phase 2 | 46 | Radboud University Medical CenterOTHER | 2 | Mar 19, 2020 | clinicaltrials |
| NCT02921061 | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02416908 | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT01744665 | A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation(ENESTgoal) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 10, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2021source: clinicaltrials